联系客服

002793 深市 罗欣药业


首页 公告 罗欣药业:2023年度财务决算报告

罗欣药业:2023年度财务决算报告

公告日期:2024-04-27

罗欣药业:2023年度财务决算报告 PDF查看PDF原文

                  罗欣药业集团股份有限公司

                    2023年度财务决算报告

        罗欣药业集团股份有限公司(以下简称“公司”)2023年度财务报表按照

    企业会计准则的规定编制,在所有重大方面公允反映了公司截至2023年12月31

    日的财务状况以及2023年度的经营成果和现金流量。天健会计师事务所(特殊

    普通合伙)已对公司财务报表进行了审计,并出具了标准无保留意见的审计报

    告。现将主要财务数据汇报如下:

        一、主要会计数据

        经审计,天健会计师事务所(特殊普通合伙)出具了标准无保留意见的审计

    报告,2023年公司实现营业收入2,363,867,226.54元,较上年下降34.11%。归属于

    上市公司股东的净利润-661,138,090.85元,较去年上升46.03%。

        最近三年公司主要会计数据:

                                                                          单位:元

                                  2022 年          本年比上年          2021 年

              2023 年                                增减

                            调整前      调整后      调整后      调整前      调整后

营 业 收 入  2,363,867,22  3,587,547,04  3,587,547,04      -34.11%  6,477,932,59  6,477,932,59
(元)              6.54        0.11        0.11                      0.01        0.01

归属于上市            -            -            -              406,096,223.  406,258,905.
公司股东的  661,138,090.  1,225,541,30  1,224,926,57      46.03%          38          57
净利润(元)          85        5.23        2.67

归属于上市

公司股东的            -            -            -              351,263,669.  351,426,351.
扣除非经常  638,852,617.  1,448,848,48  1,448,233,75      55.89%          11          30
性损益的净          29        9.02        6.46

利润(元)

经营活动产  466,888,340.            -            -              120,632,955.  120,632,955.
生的现金流          77  939,126,902.  939,126,902.    149.72%          51          51
量净额(元)                      89          89

基本每股收        -0.61        -0.86        -0.86      29.07%        0.28        0.28
益(元/股)

稀释每股收        -0.61        -0.86        -0.86      29.07%        0.28        0.28
益(元/股)

加权平均净      -23.42%      -32.44%      -32.44%      9.02%      9.63%      9.63%
资产收益率

                                  2022 年末          本年末比上          2021 年末

              2023 年末                              年末增减

                            调整前      调整后      调整后      调整前      调整后

总资产(元)  5,117,407,33  8,107,824,38  8,118,889,99      -36.97%  9,496,829,75  9,505,902,57
                    2.82        9.64        2.16                      9.91        4.09


 归属于上市  2,469,901,45  3,174,106,04  3,174,884,23              4,384,586,51  4,384,749,19
 公司股东的        3.15        3.42        1.41      -22.20%        4.05        6.24
 净资产(元)

        二、占公司营业收入10%以上的产品收入及毛利率情况

                                                                          单位:元

              营业收入      营业成本      毛利率  营业收入比上 营业成本比上 毛利率比上年
                                                      年同期增减  年同期增减  同期增减

抗生素类    908,058,528.68  611,397,673.38      32.67%      14.30%      23.49%      -5.01%

消化系统类  571,798,156.60  201,048,288.13      64.84%    163.63%      73.04%      18.41%

呼吸系统类  245,265,975.24  128,762,399.32      47.50%    437.81%      33.26%      159.38%

其他类      348,413,368.45  144,047,335.91      58.66%    -10.83%      2.68%      -5.44%

代理产品    255,057,170.18  172,936,237.23      32.20%    -87.39%    -89.77%      15.79%

        三、资产及负债状况分析

                                                                          单位:元

                    2023 年末                2023 年初          比重增

                金额      占总资      金额      占总资    减        重大变动说明
                            产比例                  产比例

 货币资金    692,899,478.54  13.54%  1,433,805,083.16  17.66%  -4.12%  本期偿还借款

 应收账款    504,542,381.19    9.86%  868,641,770.47  10.70%  -0.84%  本期收回前期应收款
                                                                        项

 存货        455,611,306.50    8.90%  684,985,514.25    8.44%    0.46%  本期加强存货管理,
                                                                        降低库存水平

 长期股权  184,634,863.54    3.61%  170,562,950.76    2.10%    1.51%

 投资

 固定资产  1,247,031,660.68  24.37%  1,409,329,098.75  17.36%    7.01%

 在建工程    336,860,300.86    6.58%  294,224,521.91    3.62%    2.96%

 使用权资    45,657,468.33    0.89%    73,719,285.84    0.91%  -0.02%  办公场地租赁减少
 产

                                                                        本期偿还借款,同时
 短期借款    555,602,953.75  10.86%  2,378,252,502.05  29.29%  -18.43%  优化长短期借款比例
                                                                        导致短期借款减少

 合同负债    134,281,640.76    2.62%  169,282,523.61    2.09%    0.53%

 长期借款    429,232,204.34    8.39%  190,927,204.38    2.35%    6.04%  本期优化长短期借款
                                                                        比例导致长期借款增


                                                                        加

 租赁负债    39,073,896.73    0.76%    62,882,684.59    0.77%  -0.01%  办公场地租赁减少

 其他应收  115,710,762.78    2.26%  1,269,366,454.06  15.63%  -13.37%  本期收回财务资助款
 款                                                                    导致其他应收款减少

 其他流动                                                              本期待抵扣进项税减
 资产        57,874,315.72    1.13%  269,398,778.93    3.32%  -2.19%  少导致其他流动资产
                                                        
[点击查看PDF原文]